The Fly | GHRS

Over a week ago

Psychedelic: Enveric initiates IND-enabling genotoxicity studies of EB-003

Jun 4, 10:57 AM

GH Research announces publication of Phase 2a results for mebufotenin

GHRS

Jun 4, 10:37 AM

Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings

May 21, 11:26 AM

GH Research price target lowered by $5 at H.C. Wainwright, here's why

GHRS

May 19, 6:03 AM

GH Research price target raised by $10 at Cantor Fitzgerald, here's why

GHRS

May 15, 7:57 AM

GH Research price target lowered by $3 at Citizens, here's why

GHRS

May 15, 5:38 AM

Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings

May 14, 11:09 AM

GH Research files $400M mixed securities shelf

GHRS

May 14, 9:22 AM

GH Research reports Q1 EPS (31c), consensus (26c)

GHRS

May 14, 7:23 AM

What You Missed On Wall Street On Monday

+33

Apr 20, 4:21 PM

Midday Fly By: QXO to acquire TopBuild, Lilly to buy Kelonia

+34

Apr 20, 11:53 AM

GH Research 'welcomes' Executive Order to accelerate mental illness treatments

GHRS

Apr 20, 9:08 AM

Trump Trade: President to sign order on psychedelic used for PTSD

Apr 17, 9:53 AM

Trump to sign order on psychedelic used for PTSD, CBS News says

Apr 16, 12:04 PM

Psychedelic: Compass Pathways, NRx Pharma report earnings results

Mar 26, 10:57 AM

GH Research announces publication of Phase 2b results for mebufotenin

GHRS

Mar 25, 11:13 AM

Psychedelic: Clearmind advances recruitment for CMND-100 trial's third cohort

Mar 12, 10:24 AM

GH Research price target raised by $5 at Guggenheim, here's why

GHRS

Mar 10, 6:56 AM

GH Research price target raised by $3 at Citizens, here's why

GHRS

Mar 6, 5:43 AM

Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results

Mar 5, 10:14 AM

GH Research reports FY25 EPS (79c), consensus (82c)

GHRS

Mar 5, 7:03 AM

Psychedelic: Analyst raises Compass, Definium, GH Research price targets

Jan 29, 10:26 AM

GH Research price target raised by $7 at RBC Capital, here's why

GHRS

Jan 23, 2:24 PM

Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial

Jan 8, 10:57 AM

GH Research price target raised by $10 at Needham, here's why

GHRS

Jan 6, 7:40 AM

Proprietary Compound Portfolio: Gh Research possesses a pipeline of novel, patentable psychedelic compounds like GH001 (an IV formulation of 5-MeO-DMT), GH002, and GH003, providing a unique and protected approach distinct from generic substances.

Differentiated Delivery and Formulation: Their lead candidate, GH001, is an intravenous formulation, offering precise dosing control, rapid onset of action, and potentially a more controlled clinical experience compared to oral alternatives.

Focus on High Unmet Medical Need: The company strategically targets severe psychiatric disorders such as Treatment-Resistant Depression (TRD) and Bipolar II Depression, areas with significant patient suffering and limited effective treatment options, positioning them for high market impact if successful.

Clinical Trial Success Uncertainty: The success of GH Research's clinical trials for its 5-MeO-DMT drug candidates is not guaranteed, and unfavorable results could delay or terminate product development.

Regulatory Approval Challenges: GH Research faces significant regulatory hurdles to obtain necessary approvals from health authorities, and there is no assurance that its drug candidates will receive marketing authorization.

Intense Market Competition: GH Research operates in a highly competitive pharmaceutical landscape, and its current or future drug candidates may not achieve market acceptance or may be outcompeted by rival products.